Quest Diagnostics has had mixed performance on the market, with its shares down by 1.8% since the last
Earnings Report. However, it has seen a significant rally of 25.6% over the year. The company continues to offer value and reliability as a
Momentum Stock. It recently held its 2025 Annual Meeting of Stockholders where the
Board of Directors was elected and the
Quarterly Cash Dividend was declared. The appointment of
Adrienne Brott as Senior Vice President and Chief Quality and Regulatory Affairs Officer is a key update, and the company's CEO has revealed ambitious plans for future growth.
Quest Diagnostics also completed the acquisition of the Outreach Lab Services Business of University Hospitals and is exploring new strategies such as introducing Health Coaching on their website. Their partnership with
Google Cloud AI and the unveiling of the
Alzheimer's Blood Test are significant innovative steps. Other financial highlights include their Q1 2025 Earnings Call which demonstrated strong Revenue Growth. The stock recently hit an all-time high of $179.37.
Quest Diagnostics DGX News Analytics from Wed, 03 Jul 2024 07:00:00 GMT to Fri, 23 May 2025 13:17:45 GMT -
Rating 7
- Innovation 8
- Rumor 2
